- Ascendis Pharma (NasdaqGS:ASND) and BioMarin Pharmaceutical signed a worldwide settlement and license agreement covering C-type natriuretic peptide patents and products.
- The deal resolves all ongoing litigation between the two drugmakers related to TransCon CNP, also known as navepegritide or Yuviwel.
- BioMarin granted Ascendis a non-exclusive, global license to develop and commercialize CNP-related therapies for all indications, with royalties to be paid.
- Beyond this CNP settlement and license deal, Ascendis Pharma has other drivers and risks that matter for long term investors. We have also spotted 1 major warning sign worth knowing about at Ascendis Pharma.
Zooming out from rare disease agreements like this, you may want to compare Ascendis with a wider mix of resilient, lower-risk stocks through 31 resilient stocks with low risk scores.
Ascendis Pharma focuses on TransCon based therapies that aim to address unmet medical needs across Europe, the US, and other regions, so broader access to C-type natriuretic peptide rights fits directly into its core drug development approach. With a market value of about $15.0b, it sits among larger biotechs pursuing specialized treatments rather than broad primary care products.
4 things going right for Ascendis Pharma that this headline doesn't cover.
How does this settlement reshape Ascendis Pharma's CNP opportunity?
The deal gives Ascendis a non exclusive, global license to use BioMarin's C type natriuretic peptide patents across all current and future indications for TransCon CNP, including achondroplasia and hypochondroplasia. That removes the risk of injunctions or patent setbacks around Yuviwel and allows the business to plan trials, combinations and launches under a single, known framework.
Does this change the Ascendis Pharma Narrative investors have been using?
The agreement aligns with the existing Narrative that TransCon CNP is intended to be a third pillar next to YORVIPATH and SKYTROFA. It also locks in a royalty cost of 20% on US Yuviwel sales and 18% in the EU, Brazil and South Korea until May 2030. This supports the catalyst around achondroplasia rollout, while also underlining the risk that higher operating expenses and revenue sharing could squeeze margins if product sales do not scale as analysts expect.
See how these catalysts shape Ascendis Pharma's path to a $309 fair value.
What should investors watch next for this Yuviwel deal to really matter?
The key tests now sit in commercial execution and regulatory follow through, including how US Yuviwel demand develops through 2027 and whether the European Medicines Agency approves the product on the timeline Ascendis has guided to the market. Royalty payments to BioMarin only become material if net sales ramp meaningfully across the US, EU, Brazil and South Korea before May 2030.
One piece of the Ascendis Pharma story this article has not tackled
Headline figures only tell part of the story for Ascendis Pharma, and recent checks flag something important about how those reported profits are built beneath the surface. See what our checks flag about the quality of Ascendis Pharma's earnings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com